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Summary  
Background The immobilisation of the lower leg is associated with deep vein thrombosis (DVT). However, 
thromboprophylaxis in patients with a below-knee plaster cast remains controversial. We examined the  
efficacy and safety of nadroparin and fondaparinux to ascertain the need for thromboprophylaxis in these  
patients.   
Methods PROTECT was a randomised, controlled, single-blind, multicentre study that enrolled adults with an  
ankle or foot fracture who required immobilisation for a minimum of four weeks. The patients were randomly  
assigned (1:1:1) to a control group (no thromboprophylaxis) or to one of the intervention groups: daily  
subcutaneous self-injection of either nadroparin (2850 IE anti-Xa = 0·3 ml) or fondaparinux (2·5 mg = 0·5 ml). A 
venous duplex sonography was performed after the removal of the cast or earlier if thrombosis was suspected.  
The primary outcome was the relative risk of developing DVT in the control group compared with that in both  
intervention groups. This trial is registered at ClinicalTrials.gov, number NCT00881088.   
Results Between April 2009 and December 2015, 467 patients were enrolled and assigned to either the  
nadroparin group (n=154), the fondaparinux group (n=157), or the control group (n=156). A total of 273  
patients (92, 92, and 94 patients, respectively) were analysed. The incidence of DVT in the nadroparin group  
was 2/92 (2·2%) compared with 11/94 (11·7%) in the control group, with a relative risk of 5.4 (95% CI 1·2 – 
23·6; p = 0·011). The incidence of DVT in the fondaparinux group was 1/92 (1·1%), yielding a relative risk of 10· 
8 (95% CI 1·4 – 80·7; p = 0·003) compared with that in the control group. No major complications occurred in 
any group.   
Conclusion Thromboprophylaxis with nadroparin or fondaparinux significantly reduces the risk of DVT in  
patients with an ankle or foot fracture who were treated in a below-knee cast without any major adverse  
events. 
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Introduction 
Deep vein thrombosis (DVT) is a well-recognised complication after trauma and subsequent immobilisation. 
However, for several injuries, no consensus exists on the way to prevent this complication or even on the need 
to prevent it.1 In particular, the prophylaxis of venous thromboembolism (VTE) in patients who are treated 
conservatively in a below-knee plaster cast is controversial; therefore, there is large variation in whether to 
prescribe pharmacological thromboprophylaxis in daily clinical practice.2–4 
 
The incidence of DVT in patients with a below-knee plaster cast without thromboprophylaxis ranges from 4% to 
19%.5–10 Although meta-analyses suggest that thromboprophylaxis significantly reduces the risk of DVT,11,12 
most guidelines advise against the routine use of pharmacological prophylaxis in these patients because of the 
lack of sufficient evidence, also debating the clinical significance of asymptomatic DVT and the cost-
effectiveness of thromboprophylaxis.13–15 
 
Previous randomised controlled studies have assessed the use of low-molecular-weight heparins after leg 
injury; however, no clear distinction was made among fractures and rupture of the Achilles tendon, operative 
and conservative treatment, and above- or below-knee plaster casts.7–10,16,17 All of these variables are possible 
confounders of the results. 
 
The objective of this multicentre randomised controlled trial was to assess the incidence of DVT in patients 
with a conservatively treated fracture of the ankle or foot immobilised in a below-knee plaster cast and to 
evaluate the efficacy and safety of subcutaneously administered low-molecular-weight heparin (LMWH) 
nadroparin and synthetic factor-Xa-inhibitor fondaparinux.  
 
 
Methods 
Study design 
A prospective, randomised, controlled, single-blind, multicentre study was performed between April 2009 and 
December 2015 in seven Dutch hospitals (the participating investigators are listed in the Appendix). All study 
documents and procedures were approved by the appropriate institutional review boards and ethics 
committees at each study site, and the study was performed according to the principles of the Declaration of 
Helsinki. All patients received written and verbal information about the trial, and written consent was obtained 
from each participant. The study protocol is available at http://www.protectstudie.nl/html/studyProtocol.html.  
This trial was registered at clinicaltrials.gov, number NCT00881088. 
 
Patients 
We enrolled adults (≥18 years) diagnosed with a fracture of the ankle or foot who required non-surgical 
treatment with immobilisation in a below-knee plaster cast for a minimum of four weeks. The exclusion criteria 
included the following: a delay between injury and the emergency department (ED) visit of more than 72 
hours; a known hypersensitivity to nadroparin or fondaparinux; a history of venous thromboembolism; patients 
who were already on continuous anticoagulant therapy; hypercoagulability; a bleeding tendency/disorder; 
pregnancy or lactation; ‘active’ malignancy; a severe hepatic or renal impairment (deficiency of clotting factors 
or creatinine clearance < 30 ml/min); retinopathy; previous or active bleeding from the digestive tract; a 
haemorrhagic stroke within the previous two months; a major surgery within the previous two months; an 
intraocular/spinal/brain surgery within the previous year; and severe hypertension (systolic blood pressure 
above 180 mmHg or diastolic blood pressure above 110 mmHg).  
The following risk factors for DVT were recorded: age, sex, body-mass index (BMI), current smoking, use of 
oestrogen-containing hormonal replacement therapy, oral contraception and varicose veins. 
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Randomisation and masking 
After meeting the aforementioned inclusion criteria and obtaining informed consent, patients were enrolled 
and randomly assigned (by use of sealed, numbered envelopes in a ratio of 1:1:1 in blocks of 15, stratified 
according to centre) to one of the three study groups by the treating physician at the ED. The treating physician 
at the ED was not involved in the remainder of the trial. 
The ultrasound technician who assessed the primary outcome was blinded to the treatment.  
 
Procedures 
The participants in the intervention groups were instructed by a trained nurse to subcutaneously self-inject 
either nadroparin (2850 IE anti-Xa = 0·3 ml, given once daily) or fondaparinux (2·5 mg = 0·5 ml, given once 
daily). These dosages are standard for the use in thromboprophylaxis. The participants were given pre-filled 
disposable syringes for once-daily administration during the duration of the immobilisation.  
The participants received a letter that explained the clinical symptoms associated with the possible 
development of DVT, pulmonary embolism (PE) and side effects of the medication and were asked to contact 
the ED if any of these occurred. Any signs of VTE or side effects were evaluated by the physician who was 
present at the removal of the cast and documented on the case report form. 
By counting the number of used syringes at the end of the study period and by asking the patient how many 
injections they had missed, we assessed the participants’ compliance with the study.  
 
A venous duplex sonography of the affected leg was performed after removal of the cast on the final day of 
medication administration or earlier if thrombosis was suspected.  
The duplex sonography was performed by experienced technicians according to a strict diagnostic test protocol 
that systematically assessed the veins of the lower extremity (Appendix 1). When a vein was incompressible or 
lacked flow, a diagnosis of DVT was made.  
In the case of a suspected pulmonary embolism, a CT angiography of the lungs was performed. 
 
Outcomes 
Efficacy (primary endpoint) was assessed by the percentage of patients in each intervention group who had 
developed a DVT verified by duplex sonography and/or a symptomatic pulmonary embolism verified by CT 
angiography compared with those of the control group.  
Safety (secondary endpoint) was measured by recording adverse events, such as major bleeding, injection site 
haematomas and other minor bleedings, and allergic reactions. 
 
Statistical analysis and data management 
The sample size calculation yielded a necessary 223 patients in each group (sample size 669 in total) of the 
study to detect a reduction in the cumulative incidence of DVT from 10% in the control group (based on 
available literature) to 4% in the intervention groups, assuming a power of 80% and a one-sided significance 
level of 0·05. The number needed to treat was 17. The dropout rate was estimated to be 15%; thus, the 
number of subjects to be included was 770. 
The primary analysis was performed according to the intention-to-treat principle. Patients who received at 
least one dose of the study medication were included in the analyses of efficacy and safety if a venous duplex 
sonography was obtained.  
 
A comparison was made between each intervention group and the control group. The primary and secondary 
outcome measures were analysed using a chi-square test or Fisher’s exact test for dichotomous variables and 
Student’s T-test for continuous variables. A p-value less than 0·05 was considered statistically significant in all 
tests. The data were analysed using SPSS statistical software (version 22.0.0.0). The study design, data entry, 
editing, and analyses were all carried out by the authors.  
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Role of the funding source 
The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or 
writing of the report. All the authors had full access to all of the data and were responsible for the decision to 
submit for publication.  
 
 
Results 
From April 1st, 2009 to December 31th, 2015, 783 patients were assessed for eligibility; 316 were ineligible for 
the study. After this period, we stopped the patient recruitment because there were formal stopping rules 
regarding the duration of the study and the scheduled date of closure that were agreed upon by the review 
boards and ethics committees.  
 
Among the 467 patients enrolled, 154 were randomly assigned to receive nadroparin, 157 to receive 
fondaparinux and 156 to the control group. A total of 189 patients were lost to follow up in the efficacy analysis 
(Figure 1) because at the reassessment after one week no fracture was diagnosed, there were indications for 
surgical treatment or the patients were treated without a below-knee plaster cast for the duration of four 
weeks; thus, these patients fell outside the inclusion criteria or no duplex sonography was performed and the 
primary outcome could not be analysed. Two patients in the nadroparin group stopped because of an allergic 
reaction and no ultrasound was performed. In the control group, two patients were excluded during the study 
period; one was excluded because of a diagnosis of malignancy and the other because of surgery for an 
aneurysm of the abdominal aorta. Thus, 273 patients (94 in the control group, 92 in the nadroparin group and 
92 in the fondaparinux group) were included in the intention-to-treat analysis.  
 
Figure 1: Trial profile 
 
 
 
The baseline characteristics and risk factors for vascular disease were similar in all three groups (Table 1). 
 
Table 1: Baseline characteristics of the intention-to-treat population 
Characteristics Control Nadroparin  Fondaparinux 
783 patients assessed for eligibility 
467 patients randomly assigned 
316 were ineligible for the study 
140  did not meet eligibility criteria 
176  did not give consent 
157 assigned to receive fondaparinux 156 assigned to control group 154 assigned to receive nadroparin 
62 withdrew 
5 no fracture 
18  no plaster cast 
9  indication for surgery 
5 immobilisation < 4 weeks 
17  no duplex sonography 
6  withdrew consent 
2  other 
65 withdrew 
4  no fracture 
18 no plaster cast 
15  indication for surgery 
7 immobilisation < 4 weeks 
19  no duplex sonography 
2  withdrew consent 
0  other 
62 withdrew 
2 no fracture 
21  no plaster cast 
10  indication for surgery 
4  immobilisation < 4 weeks 
23  no duplex sonography 
0  withdrew consent 
2  other 
92 completed study 94 completed study 92 completed study 
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(n = 94) (n = 92) (n = 92) 
Age (years) 44·5 (17·2) 47·7 (16·4) 49·7 (17·3) 
Male sex 38 (40%) 39 (42%) 41 (45%)  
Body-mass index  25·1 (3·8) 26·4 (4·5) 26·5 (4·1) 
Current smoking 29 (33%) 28 (32%) 18 (21%) 
Current hormone therapy  8 (9%) 4 (5%) 6 (7%) 
Varicose veins 14 (16%) 6 (6·8%) 16 (19%) 
Duration of immobilisation (days) 40·3 (8·6)  40·2 (8·5)  38·0 (8·7) 
Data are mean (SD) or n (%). 
 
 
Compliance with the study treatment was close to 100% in both groups (data not shown).  
 
No major complications (bleeding, infection of the injection location, cutaneous necrosis) occurred in any 
group. A total of 31 patients with minor complications were from the intervention groups: 26 (19 (27·1%) in the 
nadroparin and 7 (9·6%) in the fondaparinux group) reported small haematomas, two (one in each intervention 
group (1·4%)) considered the injections to be painful, two (one in each intervention group (1·4%)) reported 
haematuria and one patient (1·4%) in the nadroparin group reported dark stools.  
 
Deep vein thrombosis was diagnosed in 11 of the patients who were randomly assigned to the control group 
(11·7%), in two of those assigned to receive nadroparin (2·2%) and in one of those assigned to receive 
fondaparinux (1·1%). Two patients with DVT in the control group presented with symptoms of pulmonary 
embolism before the removal of the cast, which was confirmed by CT angiography. None of the remaining DVT 
patients had developed symptoms of a venous thromboembolic event; thus, those DVTs were asymptomatic.  
 
Table 2: Nadroparin vs control 
 Control (n = 94) Nadroparin (n = 92) P-value* 
DVT – no. (%) 11 (11·7) 2 (2·2) 0·011 
* The P-value was calculated with the use of the Pearson Chi-Square test, 2-sided significance 
 
The analysis showed that the incidence of DVT in the group of patients treated with nadroparin was 2/92 
(2·2%) compared with 11/94 (11·7%) in the control group, with a relative risk of 5·4 (95% CI 1·2 – 23·6; p = 
0·011) (Table 2). The analysis of the group of patients treated with fondaparinux showed that the incidence of 
DVT was 1/92 (1·1%) compared with 11/94 (11·7%) in the control group, with a relative risk of 10·8 (95% CI 1·4 
– 80·7; p = 0·003) (Table 3).  
 
Table 3: Fondaparinux vs control 
 Control (n = 94) Fondaparinux (n = 92) P-value* 
DVT – no. (%) 11 (11·7) 1 (1·1) 0·003 
* The P-value was calculated with the use of the Pearson Chi-Square test, 2-sided significance 
 
 
Discussion 
This randomised controlled trial compared nadroparin or fondaparinux thromboprophylaxis in foot or ankle 
fracture patients who had been immobilised in a below-knee plaster cast for at least four weeks with a control 
group that did not receive any form of thromboprophylaxis. We found an 11·7% incidence of deep vein 
thrombosis diagnosed with venous duplex sonography in the control group. The incidence was significantly 
lower in patients who received daily subcutaneous injections of nadroparin or fondaparinux (2·2% and 1·1%, 
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respectively) during the complete period of immobilisation (p = 0·011 and p = 0·003). Two clinically significant 
PEs occurred in the control group, and the other DVTs were asymptomatic. 
 
Previous comparative studies have shown that prophylaxis with LMWH in patients immobilised with a plaster 
cast can reduce the incidence of (asymptomatic) DVT to a greater or lesser extent. As an exception, Jorgensen 
et al. found prophylaxis to be insufficiently effective in their study.7 In an RCT of 253 patients, Kock et al. found 
the incidence of DVTs with prophylaxis (nadroparin) to be significantly lower than that in their control group.8 
Kujath et al. showed the same in another RCT of 339 patients.9 This study, however, was not blinded to 
treatment. Lassen et al., in an RCT of 371 patients, showed a significant reduction in DVT with the use of LMWH 
(reviparin), but they included patients with leg fractures who underwent surgery, which is known to be an 
independent risk factor for the development of DVT.10 All of these studies were based on a heterogeneous 
group of patients with various fractures and soft-tissue injuries who were treated with or without surgery and 
the use of different means of immobilisation.  
 
The patient population in our study was well defined and consisted solely of patients with a non-surgical 
fracture that was treated in a below-knee plaster cast. We found that treatment with nadroparin or 
fondaparinux was safe. Apart from some small injection site haematomas, there were no cases of major 
bleeding in any of the groups. Compliance was excellent in our study. This suggests that prophylaxis with 
nadroparin or fondaparinux during the entire period of immobilisation is feasible, even though both 
prophylactic regimens comprised the need for subcutaneous administration.  
 
Most DVTs in our study were asymptomatic, diagnosed by venous duplex sonography (except for the two cases 
of PE in the control group). The clinical significance of such thrombi is much debated.18,19 Nevertheless, a 
thrombus is a symptom of the underlying disease process, hypercoagulopathy, which we believe should be 
treated. There is no doubt that failure to recognise post-traumatic DVT can lead to long-term damage in the 
form of post-thrombotic syndrome or pulmonary embolism.20,21 A total of 50% of pulmonary embolisms are 
caused by asymptomatic DVTs, and even small thrombi in distal veins can progress to proximal veins and cause 
major complications.22 
 
In this study, we used nadroparin and fondaparinux as a thromboprophylactic treatment and compared it with 
the control group. We chose to compare two different thromboprophylactic regimens with a control group; 
nadroparin was chosen because it is the most commonly used thromboprophylaxis in the Netherlands,3 and 
fondaparinux was chosen because at the start of the study, there were several studies that suggested that 
fondaparinux was more effective in preventing DVT compared with LMWH without proposing the risk of 
heparin induced thrombocytopenia (HIT).23–25 
We think that our results can be extrapolated to other the use of other LMWH for preventing VTE in patients 
treated with a below-knee cast, such as enoxaparin and dalteparin. Although there are no previous studies 
comparing different LMWH’s for this indication, studies comparing LMWH’s for thromboprophylaxis in critical 
ill patients show no differences in efficacy and safety.26 If any differences between LWMH preparations do 
exist, the must be extremely small.  
We decided to refrain from administering a placebo in the control group because the outcome measure was 
objective (DVT or PE diagnosed by venous duplex sonography or pulmonary CT angiography, respectively).  
 
In this study, we used venous duplex sonography to diagnose DVT. Although venography is considered the gold 
standard in this setting,27, 28 it is rarely used as a first-line investigation for DVT. It is an invasive procedure, and 
there is a reported incidence of serious adverse reactions to the contrast medium ranging from 0·4% to 2%.29 
Venous duplex sonography is the most common non-invasive test used to diagnose venous thrombosis of the 
extremities. Compared with venography, duplex ultrasound has been shown to be reliable in the diagnosis of 
proximal symptomatic DVT, with a sensitivity and specificity of over 90%. For distal DVTs, a sensitivity of 73% 
can be reached by combining compression ultrasound with colour Doppler ultrasound.14,30 This may mean that 
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the incidence of asymptomatic DVT in our study is underestimated as we used ultrasound instead of 
venography to diagnose DVT. However, this underestimation would have affected all three of the study arms. 
 
This study was prematurely terminated because of prior agreements with the review boards and ethics 
committees of the participating hospitals about the scheduled date of closure. No interim analyses were 
conducted. Unfortunately, we did not reach the sample size calculated by our power analysis during this 
period. Despite our efforts to enrol eligible patients, it proved difficult to obtain informed consent. In addition, 
a considerable number of patients were lost to follow up. This was mostly because many patients were 
excluded after one week when they failed to meet our inclusion criteria based on reassessment (they had no 
fracture, an indication for surgery was set, or they were not further treated with a below-knee plaster cast eg. 
soft-cast, etc.). The number of patients lost to follow up was divided equally among the three groups and will 
therefore not cause bias. 
 
In conclusion, we found that thromboprophylaxis with nadroparin or fondaparinux significantly reduced the 
risk of a thromboembolic event in patients with a fracture of the ankle or foot who were conservatively treated 
with a below-knee cast without any major adverse events. We, therefore, propose to routinely prescribe 
thromboprophylaxis in these patients.  
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Appendix 1: Test protocol venous duplex sonography 
Objective 
To detect or to rule out thrombosis in the deep venous system.  
 
Preparation 
The technician explains the procedure to the patient.  
The patient takes place on the examination-bench, with bare legs, in supine position. Ensure that the patient is as relaxed as 
possible, with the upper body slightly elevated.  
 
Method 
The veins are imaged transversely from the ligament of Poupart to the ankle. By applying pressure with the probe the 
compressibility of the vein is evaluated. The vessel’s patency is evaluated by the assessment of flow.  
The vein is examined over the entire length at intervals of 5 centimeters.  
 
Investigation of these veins is performed:  
Common femoral vein 
Deep femoral vein 
Superficial femoral vein 
Popliteal vein 
Gastrocnemius vein 
Anterior tibial vein 
Posterior tibial vein 
Soleal vein 
 
When thrombosis of the common femoral vein is detected, the vein is examined up to intra-abdominally. The iliac system 
will also be reviewed and optionally the vena cava.  
 
Documentation 
All examined veins should be photographically captured using the dual mode: the left image without compression, the right 
image with compression.  
The technician fills out the Case Report Form PROTECT and concludes whether thrombosis is present or not. When 
thrombosis is present the exact location is documented.  
The completed case report form should be filed with the images of the examination. 
 
Results 
The patient is informed of the outcome of the examination and is sent back to the surgical department. Generally the 
patient can go home, unless there is an (asymptomatic) DVT. In this case the patient should be referred to the emergency 
department. 
 
 
 
 
